Clinical Trial Update: Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating insulin detemir (Levemir) in cystic fibrosis-related diabetes showed metabolic and clinical improvements. The study was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis-related Diabetes

Drugs mentioned

• Levemir (insulin detemir)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Cystic Fibrosis Related Diabetes | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2018-04-12